Egrezev

Infertility presents a significant challenge for many couples. Consequently, having a biological child has transitioned from being merely a blessing to an almost unattainable aspiration.

Diminished ovarian reserve is no longer solely an age-related issue; the likelihood of conceiving a biological child has decreased by more than 50%.

While low Anti-Müllerian Hormone (AMH) levels serve as a marker indicating diminished ovarian reserve, understanding the underlying cause is essential for identifying the most effective treatment solution.

Research indicates that activation of FOXO3 and its effects are associated with diminished ovarian reserve. Specifically, inappropriate stimulation of receptor tyrosine kinase (RKT) receptors triggers a cascade leading to AKT activation and overexpression of the FOXO3 protein.

FOXO3 contributes to the destruction of primordial follicles, thereby decreasing the number of viable eggs and ultimately reducing AMH levels.

Furthermore, it is not merely the quantity of eggs that is critical, but also their quality. Telomeres, the repetitive nucleotide sequences at the ends of chromosomes, shorten with age, which has been linked to increased oocyte aging.

Additionally, mitochondrial energy production is vital for reducing oxidative stress, preventing oocyte aging, and enhancing oocyte quality.

Egrezev is a scientific breakthrough that addresses these aspects, thereby improving both the quantity and quality of eggs.

Egrezev capsules, containing Quercetin, Resveratrol, and Melatonin, enhance ovarian reserve and inhibit premature ovarian aging.

This product is clinically validated, with its clinical study presented at the American Society for Reproductive Medicine in San Antonio, October 2025 (reference available upon request).

Egrezev may significantly improve the chances for a couple to conceive a biological child.

It offers a convenient, safe, and effective solution for women experiencing low ovarian reserve and poor ovarian response.